EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services provided preliminary approval for the transitional pass-through reimbursement scheme for the firm's proprietary Wireless Stimulation Endocardially cardiac resynchronization therapy system, according to a Tuesday Australian bourse filing.
The preliminary approval is expected to become effective in October and will be effective for three years.
The firm said it will continue to engage with the agency through the upcoming annual rulemaking and public comment process.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。